Contingency Management for Cannabis Use for Persons With HIV

Not Applicable

Recruiting

• Conditions: Marijuana; HIV Infections
• Interventions: Behavioral: Contingency Management - Cannabis

• Registration Number: NCT04866004
• Lead Sponsor: The University of Texas Health Science Center at San Antonio

Brief Summary

The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will provide motivational (monetary) incentives to participants who achieve biochemically verified cannabis abstinence. Over the 28-days of this pilot feasibility trial, participants will attend seven study visits. During these visits, participants will complete survey questionnaires to assess sociodemographic, psychosocial, and behavioral factors. In addition, participants will provide blood and urine specimens for testing and quantitation of HIV viral load, biomarkers of systemic inflammation and for the detection of cannabis and other drugs of abuse.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-27
• Study First Submitted QC: 2021-04-27
• Study First Posted: 2021-04-29
• Study Start: 2021-08-01
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-20
• Last Update Posted: 2025-02-24
• Primary Completion: 2025-07-01
• Study Completion: 2025-07-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• HIV-positive (confirmed via HIV medication or relevant HIV labs in subject's name)
• Self-report of cannabis use at least once per week in the 6-month period prior to consent
• Provide a positive urine toxicology (UTOX) screen for cannabis
• Not seeking treatment for cannabis use
• Willing to stop using cannabis for 28 days and attend eight study visits over six weeks.
• Ability and willingness to provide inform consent
• English fluency

Exclusion Criteria

• Currently receiving treatment for cannabis or other drug use disorder
• Diagnosed or receiving treatment for a current major depressive or anxiety disorder
• Diagnosed with any current alcohol or substance use disorder (excluding nicotine) using the Structured Clinical Interview for Clinical Disorders (SCID) Interview (22)
• Positive UTOX screen for opioids
• Having a medical, psychiatric, occupational, or other condition that, in the judgment of the study physician, would make participation difficult or unsafe.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Contingency Management - Cannabis	Contingency Management - Cannabis	Participants will be incentivized following biochemical verification (from urine samples) of cannabis abstinence.

Primary Outcome Measures

Name	Time	Method
Sustained cannabis abstinence for 28-days	28-days	Cannabis abstinence will be defined as sustained reduction in quantitative levels of 11-Nor-9-carboxy-Δ⁹-tetrahydrocannabinol (THCCOOH) for 28-days

Trial Locations

Locations (2)

Center for Neurobehavioral Research on Addiction; 🇺🇸 Houston, Texas, United States

University of Texas Health Science Center at San Antonio; 🇺🇸 San Antonio, Texas, United States